AustralieFrV1, Main, Curation, bibRecord, 00D415

‘Tomudex’ (ZD1694): Results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia

Identifieur interne : 00D415 ( Main/Curation ); précédent : 00D414; suivant : 00D416

‘Tomudex’ (ZD1694): Results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia

Auteurs : D. Cunningham [Royaume-Uni] ; J. R. Zalcberg [Australie] ; U. Rath [Allemagne] ; I. Olver [Australie] ; E. Van Cutsem [Belgique] ; C. Svensson [Suède] ; J. F. Scitz [France] ; P. Harper [Royaume-Uni] ; D. Kerr [Royaume-Uni] ; G. Perez-Manga [Espagne] ; M. Azab [Royaume-Uni] ; L. Seymour [Royaume-Uni] ; K. Lowery [Royaume-Uni]

Source :

European Journal of Cancer [ 0959-8049 ] ; 1995.

RBID : ISTEX:903D61F1D65AF14E506ECC99D1DA49CB73873797

Descripteurs français

Wicri :
- topic : Organisation européenne.

English descriptors

Abstract

Abstract: ‘Tomudex’ (ZD1694), a direct and specific thymidylate synthase (TS) inhibitor entered phase III studies in November 1993. We present here the first analysis of a randomised multicentre, international phase III study. 439 patients with previously untreated advanced colorectal cancer were randomised to Tomudex 3.0 mg/m2 given once every 3 weeks or 5-fluorouracil (5-FU) 425 mg/m2 and leucovorin (LV) 20 mg/m2 for 5 days (the Mayo regimen), given every 4–5 weeks. Patients were evaluated weekly for toxicity and every 12 weeks for objective response. The two groups were well matched in terms of demographic characteristics. The mean age of the patients was 61 years and most had either liver (78%) or lung (25–29%) metastases. Ninety seven per cent of patients allocated to Tomudex and 94% of those allocated to 5-FU plus LV had measurable disease. Response was assessed using WHO/UICC criteria; all response data were source validated; 19.8% of patients who received Tomudex and 12.7% of patients who received 5-FU plus LV had complete or partial responses (P = 0.059, odds ratio 1.7,95% confidence limits 0.98–2.81). There were no statistically significant differences in time to progression or survival between the two groups. Patients who received Tomudex spent a substantially shorter time in hospital for dosing and had significantly lower rates of grade 3 and 4 toxicities such as leucopenia and mucositis. Patients who received Tomudex had a significantly higher incidence of reversible grade 3 or 4 increase in transaminases, which appear to be of limited clinical significance. Improvement in quality of life, weight gain and performance status was seen in both groups. Tomudex has benefits in terms of higher response rates, reduced toxicity and more frequent palliative benefits when compared with 5-FU plus LV in the management of advanced colorectal cancer, and has a more convenient administration schedule.

Url:

https://api.istex.fr/document/903D61F1D65AF14E506ECC99D1DA49CB73873797/fulltext/pdf

DOI: 10.1016/0959-8049(95)00502-1

Links toward previous steps (curation, corpus...)

to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001B33
to stream Istex, to step Curation: Pour aller vers cette notice dans l'étape Curation :001B33
to stream Istex, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :002692
to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :00E616

Links to Exploration step

ISTEX:903D61F1D65AF14E506ECC99D1DA49CB73873797

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>‘Tomudex’ (ZD1694): Results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia</title>
<author><name sortKey="Cunningham, D" sort="Cunningham, D" uniqKey="Cunningham D" first="D." last="Cunningham">D. Cunningham</name>
</author>
<author><name sortKey="Zalcberg, J R" sort="Zalcberg, J R" uniqKey="Zalcberg J" first="J. R." last="Zalcberg">J. R. Zalcberg</name>
</author>
<author><name sortKey="Rath, U" sort="Rath, U" uniqKey="Rath U" first="U." last="Rath">U. Rath</name>
</author>
<author><name sortKey="Olver, I" sort="Olver, I" uniqKey="Olver I" first="I." last="Olver">I. Olver</name>
</author>
<author><name sortKey="Van Cutsem, E" sort="Van Cutsem, E" uniqKey="Van Cutsem E" first="E." last="Van Cutsem">E. Van Cutsem</name>
</author>
<author><name sortKey="Svensson, C" sort="Svensson, C" uniqKey="Svensson C" first="C." last="Svensson">C. Svensson</name>
</author>
<author><name sortKey="Scitz, J F" sort="Scitz, J F" uniqKey="Scitz J" first="J. F." last="Scitz">J. F. Scitz</name>
</author>
<author><name sortKey="Harper, P" sort="Harper, P" uniqKey="Harper P" first="P." last="Harper">P. Harper</name>
</author>
<author><name sortKey="Kerr, D" sort="Kerr, D" uniqKey="Kerr D" first="D." last="Kerr">D. Kerr</name>
</author>
<author><name sortKey="Perez Manga, G" sort="Perez Manga, G" uniqKey="Perez Manga G" first="G." last="Perez-Manga">G. Perez-Manga</name>
</author>
<author><name sortKey="Azab, M" sort="Azab, M" uniqKey="Azab M" first="M." last="Azab">M. Azab</name>
</author>
<author><name sortKey="Seymour, L" sort="Seymour, L" uniqKey="Seymour L" first="L." last="Seymour">L. Seymour</name>
</author>
<author><name sortKey="Lowery, K" sort="Lowery, K" uniqKey="Lowery K" first="K." last="Lowery">K. Lowery</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:903D61F1D65AF14E506ECC99D1DA49CB73873797</idno>
<date when="1995" year="1995">1995</date>
<idno type="doi">10.1016/0959-8049(95)00502-1</idno>
<idno type="url">https://api.istex.fr/document/903D61F1D65AF14E506ECC99D1DA49CB73873797/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001B33</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001B33</idno>
<idno type="wicri:Area/Istex/Curation">001B33</idno>
<idno type="wicri:Area/Istex/Checkpoint">002692</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">002692</idno>
<idno type="wicri:doubleKey">0959-8049:1995:Cunningham D:tomudex:zd:results</idno>
<idno type="wicri:Area/Main/Merge">00E616</idno>
<idno type="wicri:Area/Main/Curation">00D415</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a">‘Tomudex’ (ZD1694): Results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia</title>
<author><name sortKey="Cunningham, D" sort="Cunningham, D" uniqKey="Cunningham D" first="D." last="Cunningham">D. Cunningham</name>
<affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>CRC Section of Medicine, Institute of Cancer Research and Royal Marsden Hospital, Sutton</wicri:regionArea>
<wicri:noRegion>Sutton</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Zalcberg, J R" sort="Zalcberg, J R" uniqKey="Zalcberg J" first="J. R." last="Zalcberg">J. R. Zalcberg</name>
<affiliation wicri:level="1"><country xml:lang="fr">Australie</country>
<wicri:regionArea>Heidelberg Repatriation Hospital, Victoria</wicri:regionArea>
<wicri:noRegion>Victoria</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Rath, U" sort="Rath, U" uniqKey="Rath U" first="U." last="Rath">U. Rath</name>
<affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Med Klinik der Universität, Heidelberg</wicri:regionArea>
<placeName><region type="land" nuts="1">Bade-Wurtemberg</region>
<region type="district" nuts="2">District de Karlsruhe</region>
<settlement type="city">Heidelberg</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Olver, I" sort="Olver, I" uniqKey="Olver I" first="I." last="Olver">I. Olver</name>
<affiliation wicri:level="1"><country xml:lang="fr">Australie</country>
<wicri:regionArea>Royal Adelaide Hospital, Adelaide</wicri:regionArea>
<wicri:noRegion>Adelaide</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Van Cutsem, E" sort="Van Cutsem, E" uniqKey="Van Cutsem E" first="E." last="Van Cutsem">E. Van Cutsem</name>
<affiliation wicri:level="1"><country xml:lang="fr">Belgique</country>
<wicri:regionArea>UZ Gasthuisberg, Leuven</wicri:regionArea>
<wicri:noRegion>Leuven</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Svensson, C" sort="Svensson, C" uniqKey="Svensson C" first="C." last="Svensson">C. Svensson</name>
<affiliation wicri:level="3"><country xml:lang="fr">Suède</country>
<wicri:regionArea>Sodersjukhuset, Stockholm</wicri:regionArea>
<placeName><settlement type="city">Stockholm</settlement>
<region nuts="2">Svealand</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Scitz, J F" sort="Scitz, J F" uniqKey="Scitz J" first="J. F." last="Scitz">J. F. Scitz</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>Institute Paoli Calmette, Marseille</wicri:regionArea>
<placeName><region type="region">Provence-Alpes-Côte d'Azur</region>
<region type="old region">Provence-Alpes-Côte d'Azur</region>
<settlement type="city">Marseille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Harper, P" sort="Harper, P" uniqKey="Harper P" first="P." last="Harper">P. Harper</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Guy's Hospital, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kerr, D" sort="Kerr, D" uniqKey="Kerr D" first="D." last="Kerr">D. Kerr</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Queen Elizabeth Hospital, Birmingham</wicri:regionArea>
<placeName><settlement type="city">Birmingham</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Midlands de l'Ouest</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Perez Manga, G" sort="Perez Manga, G" uniqKey="Perez Manga G" first="G." last="Perez-Manga">G. Perez-Manga</name>
<affiliation wicri:level="3"><country xml:lang="fr">Espagne</country>
<wicri:regionArea>Hospital Gregorio Maranon, Madrid</wicri:regionArea>
<placeName><settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Azab, M" sort="Azab, M" uniqKey="Azab M" first="M." last="Azab">M. Azab</name>
<affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Zeneca Pharmaceuticals Ltd, Macclesfield</wicri:regionArea>
<wicri:noRegion>Macclesfield</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Seymour, L" sort="Seymour, L" uniqKey="Seymour L" first="L." last="Seymour">L. Seymour</name>
<affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Zeneca Pharmaceuticals Ltd, Macclesfield</wicri:regionArea>
<wicri:noRegion>Macclesfield</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lowery, K" sort="Lowery, K" uniqKey="Lowery K" first="K." last="Lowery">K. Lowery</name>
<affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Zeneca Pharmaceuticals Ltd, Macclesfield</wicri:regionArea>
<wicri:noRegion>Macclesfield</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">European Journal of Cancer</title>
<title level="j" type="abbrev">EJC</title>
<idno type="ISSN">0959-8049</idno>
<imprint><publisher>ELSEVIER</publisher>
<date type="published" when="1995">1995</date>
<biblScope unit="volume">31</biblScope>
<biblScope unit="issue">12</biblScope>
<biblScope unit="page" from="1945">1945</biblScope>
<biblScope unit="page" to="1954">1954</biblScope>
</imprint>
<idno type="ISSN">0959-8049</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0959-8049</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvant chemotherapy</term>
<term>Adverse events</term>
<term>Appetite loss</term>
<term>Baseline</term>
<term>Biochemical modulation</term>
<term>Cancer deaths</term>
<term>Cancer research</term>
<term>Chemotherapy</term>
<term>Clin</term>
<term>Clin oncol</term>
<term>Colorectal</term>
<term>Colorectal cancer</term>
<term>Colorectal clin</term>
<term>Complete response</term>
<term>Complete responses</term>
<term>Consecutive days</term>
<term>Convenient dosing schedule</term>
<term>Diarrhoea</term>
<term>Disease progression</term>
<term>Dose reductions</term>
<term>Dosing</term>
<term>Efficacy analyses</term>
<term>Eurj cancer</term>
<term>European community</term>
<term>European organisation</term>
<term>Evaluable disease</term>
<term>Financial impact</term>
<term>Fluorouracil</term>
<term>Folinic acid</term>
<term>Hazard ratio</term>
<term>High dose</term>
<term>High dose leucovorin</term>
<term>Inhibitor</term>
<term>Leucopenia</term>
<term>Leucovorin</term>
<term>Liver metastases</term>
<term>Lower incidences</term>
<term>Lung metastases</term>
<term>Mayo clinic</term>
<term>Mayo regimen</term>
<term>Measurable disease</term>
<term>Measurable lesions</term>
<term>Median</term>
<term>Median time</term>
<term>Metastatic colorectal cancer</term>
<term>Mucositis</term>
<term>Nat1 cancer inst</term>
<term>Novel approaches</term>
<term>Objective response</term>
<term>Objective response rate</term>
<term>Objective responses</term>
<term>Objective tumour response</term>
<term>Odds ratio</term>
<term>Oral effects</term>
<term>Overall objective response</term>
<term>Partial responses</term>
<term>Performance status</term>
<term>Plenum press</term>
<term>Progression</term>
<term>Randomised</term>
<term>Randomised trial</term>
<term>Range cycles</term>
<term>Regimen</term>
<term>Response rate</term>
<term>Royal marsden hospital</term>
<term>Significant difference</term>
<term>Significant differences</term>
<term>Source data</term>
<term>Specific thymidylate synthase</term>
<term>Thymidylate synthase inhibitor</term>
<term>Tomudex</term>
<term>Toxicity</term>
<term>Toxicity symptoms</term>
<term>Transaminase</term>
<term>Transaminase levels</term>
<term>Treatment administration</term>
<term>Treatment group</term>
<term>Treatment groups</term>
<term>Trial therapy</term>
<term>Tumour</term>
<term>Victoria prof</term>
<term>Weight gain</term>
<term>World health organisation</term>
<term>Zeneca pharmaceuticals</term>
</keywords>
<keywords scheme="Teeft" xml:lang="en"><term>Adjuvant chemotherapy</term>
<term>Adverse events</term>
<term>Appetite loss</term>
<term>Baseline</term>
<term>Biochemical modulation</term>
<term>Cancer deaths</term>
<term>Cancer research</term>
<term>Chemotherapy</term>
<term>Clin</term>
<term>Clin oncol</term>
<term>Colorectal</term>
<term>Colorectal cancer</term>
<term>Colorectal clin</term>
<term>Complete response</term>
<term>Complete responses</term>
<term>Consecutive days</term>
<term>Convenient dosing schedule</term>
<term>Diarrhoea</term>
<term>Disease progression</term>
<term>Dose reductions</term>
<term>Dosing</term>
<term>Efficacy analyses</term>
<term>Eurj cancer</term>
<term>European community</term>
<term>European organisation</term>
<term>Evaluable disease</term>
<term>Financial impact</term>
<term>Fluorouracil</term>
<term>Folinic acid</term>
<term>Hazard ratio</term>
<term>High dose</term>
<term>High dose leucovorin</term>
<term>Inhibitor</term>
<term>Leucopenia</term>
<term>Leucovorin</term>
<term>Liver metastases</term>
<term>Lower incidences</term>
<term>Lung metastases</term>
<term>Mayo clinic</term>
<term>Mayo regimen</term>
<term>Measurable disease</term>
<term>Measurable lesions</term>
<term>Median</term>
<term>Median time</term>
<term>Metastatic colorectal cancer</term>
<term>Mucositis</term>
<term>Nat1 cancer inst</term>
<term>Novel approaches</term>
<term>Objective response</term>
<term>Objective response rate</term>
<term>Objective responses</term>
<term>Objective tumour response</term>
<term>Odds ratio</term>
<term>Oral effects</term>
<term>Overall objective response</term>
<term>Partial responses</term>
<term>Performance status</term>
<term>Plenum press</term>
<term>Progression</term>
<term>Randomised</term>
<term>Randomised trial</term>
<term>Range cycles</term>
<term>Regimen</term>
<term>Response rate</term>
<term>Royal marsden hospital</term>
<term>Significant difference</term>
<term>Significant differences</term>
<term>Source data</term>
<term>Specific thymidylate synthase</term>
<term>Thymidylate synthase inhibitor</term>
<term>Tomudex</term>
<term>Toxicity</term>
<term>Toxicity symptoms</term>
<term>Transaminase</term>
<term>Transaminase levels</term>
<term>Treatment administration</term>
<term>Treatment group</term>
<term>Treatment groups</term>
<term>Trial therapy</term>
<term>Tumour</term>
<term>Victoria prof</term>
<term>Weight gain</term>
<term>World health organisation</term>
<term>Zeneca pharmaceuticals</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Organisation européenne</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Abstract: ‘Tomudex’ (ZD1694), a direct and specific thymidylate synthase (TS) inhibitor entered phase III studies in November 1993. We present here the first analysis of a randomised multicentre, international phase III study. 439 patients with previously untreated advanced colorectal cancer were randomised to Tomudex 3.0 mg/m2 given once every 3 weeks or 5-fluorouracil (5-FU) 425 mg/m2 and leucovorin (LV) 20 mg/m2 for 5 days (the Mayo regimen), given every 4–5 weeks. Patients were evaluated weekly for toxicity and every 12 weeks for objective response. The two groups were well matched in terms of demographic characteristics. The mean age of the patients was 61 years and most had either liver (78%) or lung (25–29%) metastases. Ninety seven per cent of patients allocated to Tomudex and 94% of those allocated to 5-FU plus LV had measurable disease. Response was assessed using WHO/UICC criteria; all response data were source validated; 19.8% of patients who received Tomudex and 12.7% of patients who received 5-FU plus LV had complete or partial responses (P = 0.059, odds ratio 1.7,95% confidence limits 0.98–2.81). There were no statistically significant differences in time to progression or survival between the two groups. Patients who received Tomudex spent a substantially shorter time in hospital for dosing and had significantly lower rates of grade 3 and 4 toxicities such as leucopenia and mucositis. Patients who received Tomudex had a significantly higher incidence of reversible grade 3 or 4 increase in transaminases, which appear to be of limited clinical significance. Improvement in quality of life, weight gain and performance status was seen in both groups. Tomudex has benefits in terms of higher response rates, reduced toxicity and more frequent palliative benefits when compared with 5-FU plus LV in the management of advanced colorectal cancer, and has a more convenient administration schedule.</div>
</front>
</TEI>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 00D415 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 00D415 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    Main
   |étape=   Curation
   |type=    RBID
   |clé=     ISTEX:903D61F1D65AF14E506ECC99D1DA49CB73873797
   |texte=   ‘Tomudex’ (ZD1694): Results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

‘Tomudex’ (ZD1694): Results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia

‘Tomudex’ (ZD1694): Results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri